Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06650592 · ClinicalTrials.gov registry record
Objective Assessment of Outcomes Following Immediate Lymphatic Reconstruction / LYMPHA
A clinical trial of Lymphatic Reconstruction, sponsored by University of Chicago.
- Recruiting
- Registry status
- 90
- Enrollment target
- 1
- Study location
NCT06650592 is a study of Lymphatic Reconstruction that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 90 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06650592, a study of Lymphatic Reconstruction, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Immediate lymphatic reconstruction (ILR) is a novel surgical approach performed at the time of initial lymph node dissection with the goal of preventing lymphedema. It involves the identification of lymphatic channels that are transected after lymph node dissection and microsurgical anastomosis of one or more lymphatic channel with a local recipient vein to re-direct upper extremity lymphatic drainage. Although ILR carries significant promise in prevention of lymphedema, there is a lack of high-level evidence supporting its efficacy because it is a novel surgical technique that is only offered at a few centers and not routinely covered by insurance carriers yet. The University of Chicago Comprehensive Cancer Center (UCCCC) is one of the busiest microsurgery centers performing this procedure, and, as a Lymphedema Center of Excellence, is in a unique position to investigate the efficacy of ILR in preventing lymphedema. In addition, the University has access to a world class microbiome research facility and colleagues. There is no information on the skin microbiome of the axilla in patients undergoing treatment for breast cancer or those at risk for developing lymphedema. Further exploratory studies such as this in a diverse patient population may lead to practice changing research in our approach to lymphedema management and prevention. The purpose of this study is to determine the role of immediate lymphatic reconstruction and obtain objective data to correlate the existing, self-reported rates of lymphedema at the University of Chicago.
Conditions Studied
Interventions
- OTHER All patients who were candidates for immediate lymphatic reconstruction (ILR)
Study Locations (1)
Illinois
- The University o Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2029-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06650592
The ClinicalTrials.gov registry entry for NCT06650592 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphatic Reconstruction appearing as the primary indexed condition, and to 1 intervention - of which All patients who were candidates for immediate lymphatic reconstruction (ILR) is the first listed.
NCT06650592 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06650592 about?
NCT06650592 is a clinical study titled "Objective Assessment of Outcomes Following Immediate Lymphatic Reconstruction / LYMPHA". Immediate lymphatic reconstruction (ILR) is a novel surgical approach performed at the time of initial lymph node dissection with the goal of preventing lymphedema. It involves the identification of lymphatic channels that are transected after lymph node dissection and microsurgical anastomosis of o...
What is the current status of trial NCT06650592?
This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2024-11-26. Estimated completion is 2029-10.
What conditions does trial NCT06650592 study?
This clinical trial studies the following conditions: Lymphatic Reconstruction.
What interventions are being tested in trial NCT06650592?
The interventions under investigation include: All patients who were candidates for immediate lymphatic reconstruction (ILR) (OTHER).
Who is sponsoring clinical trial NCT06650592?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06650592 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphatic Reconstruction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.